Search Results

You are looking at 21 - 30 of 64 items for :

  • "neutropenia" x
  • Refine by Access: All Content x
Clear All

743 752 Hathorn, J. W., Lyke,. K. (1997) Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Clinical Infectious Diseases 24 , (Suppl. 2

Restricted access

Abstract

The main indication for liver transplantation is the final stage of hepatic cirrhosis developed due to hepatitis C virus (HCV) infection. The recurrence of HCV infection after transplantation is a common situation. Recurrent hepatitis C is a progressive disease; in 20% of patients it produces liver cirrhosis without treatment beside immunosuppression within 5 years. Treatment of recurrent HCV infection is the most important factor of survival in patients with transplantation. Based on literary data and their observations, the authors review the factors influencing the progression of recurrent HCV infection. They discuss in details the effect of immunosuppressive therapy, the importance of selecting appropriate immunosuppressive drugs. They review the key points in the diagnosis of recurrent hepatitis C; underline the decisive role of liver biopsy carried out according to protocol in the diagnosis, as well as the hard consultation between specialists of pathology, hepatology and surgery. They demonstrate their observations with the treatment of patients on the waiting list, the results of early pre-emptive treatment of recurrent chronic hepatitis, furthermore treatment modalities and results in patients with histologically proven chronic hepatitis C. The drug of choice for chronic hepatitis C after transplantation is combined therapy with pegylated interferon and ribavirin. This therapy is able to assure sustained virological negativity in 20–50% of patients. In virus-free patients the inflammatory activity in the liver significantly decreases, and the histologic activity index improves. There are data showing a fibrosis-inhibiting effect of the treatment, however, multicentric studies are required for their confirmation. No advantage of early antiviral treatment without histologic alteration has been confirmed by most of the trials. In this group of patients common side effects of the treatment include anaemia and neutropenia, and therefore administration of erythropoietin and granulocyte stimulating factor is recommended. Further research and clinical studies are required in order to establish optimal treatment of patients with recurrent hepatitis C, to determine the dosage of pegylated interferon and ribavirin, to decrease duration of therapy, to reduce side effects and finally to achieve the healing phase in a greater percentage of patients.

Restricted access

Onkohematológiai betegek véráram-infekcióinak epidemiológiája és prognózisa napjainkban: egy hazai centrum adatainak retrospektív elemzése

Actual epidemiology and prognosis of bloodstream infections in oncohematology patients: retrospective analysis of data from a Hungarian centre

Hematológia–Transzfuziológia
Authors: Dorina Péli, Radka Nikolova, Péter Reményi, and János Sinkó

. Antimicrob Agents Chemother. 2005; 49: 760–766. 6 Piukovics K, Terhes G, Lázás A, et al. Evaluation of bloodstream infections during chemotherapy-induced febrile neutropenia in

Open access
Orvosi Hetilap
Authors: Vera Gulácsy and László Maródi

Devriend, K., Kim, A. S., Mathijs, G. és mtsai: Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat. Genet., 2001, 27 , 313–316. Mathijs G

Restricted access

Az amfotericin B napjaink gombainfekcióinak kezelésében: meghaladott vagy korszerű terápiás lehetőség?

Amphotericin B for the treatment of present day fungal infections: an obsolete or up-to-date therapeutic option?

Hematológia–Transzfuziológia
Author: János Sinkó

–387. 29 Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single

Restricted access
Magyar Sebészet
Authors: János Tajti Jr., József Pieler, Zsolt Simonka, Attila Paszt, and György Lázár

–21. 11. D Amato JS Niblett 1977 Neutropenia from cyclophosphamide in breast milk Med J Aust

Restricted access

Multirezisztens kórokozók előfordulása hematológiai betegeinkben – a rezisztenciatrendek változása

Multidrug-resistant bacteria in hematology patients – changes in antibiotic-resistance trends

Hematológia–Transzfuziológia
Authors: Réka Ráhel Bicskó, Renáta Nyilas, Judit Szabó, Ádám Jóna, Ferenc Magyari, Mariann Szarvas, Árpád Illés, and Lajos Gergely

infection in neutropenic cancer patients. [A neutropeniás onkológiai beteg infekcióinak kezelése és megelőzése.] Magyar Onkológia 2011; 55: 155–163. [Hungarian] 4 Tóth E, Hajdú E

Open access
Orvosi Hetilap
Authors: János László Iványi, Éva Marton, and Márk Plander

of refractory immune thrombocytopenia and neutropenia with anti-CD20 monoclonal antibody. [Refrakter immunthrombocytopenia és neutropenia kezelése anti-CD20 monoklonális antitesttel.] Hematol.-Transzfuziol., 2004, 37 , 178–182. [Hungarian

Restricted access

–43. 23 Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. Blood 2014; 124: 1251–1258. 24 van den Berg JM, Kuijpers TW. Educational paper: defects in number

Restricted access
Orvosi Hetilap
Authors: Zsófia Simon, Árpád Illés, Zsófia Miltényi, Ferenc Magyari, László Váróczy, Nikolett Péter, and Lajos Gergely

, O., Bairey, O., Lahav, M.: Late-onset neutropenia after rituximab treatment. Case series and comprehensive review of the literature. Medicine, 2010, 89 , 308–318. Lahav M. Late

Restricted access